Innocan Pharma Corp. Stock
Price
Target price
€0.19
€0.19
1.570%
-
1.570%
€2.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Innocan Pharma Corp. Stock
There is an upward development for Innocan Pharma Corp. compared to yesterday, with an increase of €0.000 (1.570%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Innocan Pharma Corp..
With a target price of 2 € there is potential for a 930.93% increase which would mean more than doubling the current price of 0.19 € for Innocan Pharma Corp..
Our community identified positive and negative aspects for Innocan Pharma Corp. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Innocan Pharma Corp. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Innocan Pharma Corp. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Herzliya, Israel and Calgary, Alberta – April 1, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Herzliya, Israel and Calgary, Alberta - March 25, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug